Literature DB >> 22728164

Differential control of hypoxia-inducible factor 1 activity during pro-inflammatory reactions of human haematopoietic cells of myeloid lineage.

Bernhard F Gibbs1, Inna M Yasinska, Dmitri Pchejetski, Rafal W Wyszynski, Vadim V Sumbayev.   

Abstract

The biological responses of human haematopoietic cells of myeloid lineage following malignant transformation depends crucially on their adaptation to signalling stress. This adaptation is dependent on the activation of the hypoxia-inducible factor 1 (HIF-1) transcription complex, although the mechanisms underlying its control remain unclear. Here, we report that mammalian target of rapamycin (mTOR) kinase, a central regulator of myeloid cell growth and metabolism, is crucially involved in HIF-1α accumulation/HIF-1 activation in human THP-1 myeloid monocytes, LAD2 mast cells and primary basophils in a variety of different settings. In THP-1 cells, mTOR was a major contributor to HIF-1 activation induced by ligands of both membrane-associated and endosomal toll-like receptors that recognise molecular patterns shared by pathogens. In LAD2 mast cells and primary human basophils mTOR was vital for HIF-1α accumulation/HIF-1 activity during immunoglobulin E (IgE)-dependent pro-allergic responses as well as in maintaining constitutive HIF-1α levels in mast cells. Furthermore, we observed that nitric oxide synthase activity was dependent on mTOR in these myeloid cells and involved in HIF-1α accumulation mediated by endosomal toll-like receptor 7/8 triggering in THP-1 cells as well as IgE-dependent basophil, but not mast cell, responses. In both cases the process is likely to be associated with an impact of reactive nitrogen species on HIF-1α-degrading prolyl hydroxylation. These studies underline the importance of mTOR as a fundamental regulator of HIF-1 signalling in myeloid cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728164     DOI: 10.1016/j.biocel.2012.06.019

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  7 in total

1.  Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors.

Authors:  Alicia Báez; Beatriz Martín-Antonio; José I Piruat; Concepción Prats; Isabel Álvarez-Laderas; M Victoria Barbado; Magdalena Carmona; Álvaro Urbano-Ispizua; Jose Antonio Pérez-Simón
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

2.  Use of culture geometry to control hypoxia-induced vascular endothelial growth factor secretion from adipose-derived stem cells: optimizing a cell-based approach to drive vascular growth.

Authors:  Matthew L Skiles; Suchit Sahai; Lindsay Rucker; James O Blanchette
Journal:  Tissue Eng Part A       Date:  2013-06-26       Impact factor: 3.845

Review 3.  Hypoxia-Inducible Factor (HIF) as a Pharmacological Target for Prevention and Treatment of Infectious Diseases.

Authors:  Tamara Bhandari; Victor Nizet
Journal:  Infect Dis Ther       Date:  2014-06-24

4.  STAT3 governs the HIF-1α response in IL-15 primed human NK cells.

Authors:  Anna Coulibaly; Sonia Y Velásquez; Nina Kassner; Jutta Schulte; Maria Vittoria Barbarossa; Holger A Lindner
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

5.  HIF-1α inhibition reduces nasal inflammation in a murine allergic rhinitis model.

Authors:  Han Zhou; Xi Chen; Wei-Ming Zhang; Lu-Ping Zhu; Lei Cheng
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

6.  Crucial involvement of xanthine oxidase in the intracellular signalling networks associated with human myeloid cell function.

Authors:  Maryam Abooali; Gurprit S Lall; Karen Coughlan; Harjinder S Lall; Bernhard F Gibbs; Vadim V Sumbayev
Journal:  Sci Rep       Date:  2014-09-09       Impact factor: 4.379

7.  Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.

Authors:  Isabel Gonçalves Silva; Bernhard F Gibbs; Marco Bardelli; Luca Varani; Vadim V Sumbayev
Journal:  Oncotarget       Date:  2015-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.